Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Part of paid clinical trials in Orange, California.
- Sponsor
- University of California, Irvine
- Study ID
- NCT06580002
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Brain Cancer
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Genitourinary Cancer
- Gynecologic Cancer
- Head and Neck Cancer
- Hodgkin Lymphoma
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoid Leukemia
- Melanoma
- Mycosis Fungoides
- Myeloma Multiple
- Non-hodgkin Lymphoma
- Ovarian Cancer
- Pancreas Cancer
- Prostate Cancer
- Sarcoma
- Urinary Bladder Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Riluzole — DRUGGiven PO
- Placebo — DRUGGiven PO
Study Details
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.
Key Dates
- First listed
- Aug 30, 2024
- Start date
- Dec 2, 2024
- Status verified
- Jul 2026
- Primary completion
- Jul 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 75 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: RiluzoleStudy participants randomized to this arm will take 50 mg of riluzole twice daily (every 12 hours) for 8 weeks
- Placebo Comparator: PlaceboStudy participants randomized to this arm will take a placebo, that matches the appearance of 50 mg capsule of riluzole, twice daily (every 12 hours) for 8 weeks
Primary Outcome Measure
Change in circulating Brain-Derived Neurotrophic Factor (BDNF) levels over time in cancer survivors experiencing cognitive impairment (CRCI) [ Time Frame: 8 weeks ]
Central Contacts
- Chao Family Comprehensive Cancer Center University of California, Irvine1-877-827-8839
- University of California Irvine Medical
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Chao Family Comprehensive Cancer Center, University of California Irvine | Orange | California | 92868 |
Find similar trials in Orange, CA
By condition
By specialty
Related Studies
- Bone Marrow Grafting for Leukemia and LymphomaEnrolling By Invitation · Stanford University · Stanford, California
- Identification and Characterization of Novel Proteins and Genes in Head and Neck CancerRecruiting · Stanford University · Stanford, California
- Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung CancersRecruiting · Stanford University · Stanford, California
- Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung CancerRecruiting · University of California, Davis · Sacramento, California